Seth Lederman - 24 Feb 2026 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role: Chief Executive Officer, Director
Signature: /s/ Seth Lederman
Issuer symbol: TNXP
Transactions as of: 24 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 26 Feb 2026, 07:01:33 UTC
Previous filing: 15 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
LEDERMAN SETH	Chief Executive Officer, Director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 200 CONNEL DRIVE, SUITE 3100, BERKLEY HEIGHTS	/s/ Seth Lederman	26 Feb 2026	0001563420

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNXP	Stock Option	Award	$0	+134,504		$0.000000	134,504	24 Feb 2026	Common Stock	134,504	$14.29	Direct	F1, F2
transaction	TNXP	Stock Option	Award	$0	+134,503		$0.000000	134,503	24 Feb 2026	Common Stock	134,503	$17.86	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months.
F2	The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.